Spectral domain-optical coherence tomographic findings in patients with ankylosing spondylitis under anti-tumor necrosis factor-alpha therapy

Basit Öğe Kaydı
dc.contributor.authorIlhan, Nilufer
dc.contributor.authorUstun, Nilgul
dc.contributor.authorTuzcu, Esra Ayhan
dc.contributor.authorCoskun, Mesut
dc.contributor.authorYagiz, Abdullah Erman
dc.contributor.authorIlhan, Ozgur
dc.contributor.authorParlakfikirer, Nihan
dc.date.accessioned2024-09-18T20:29:40Z
dc.date.available2024-09-18T20:29:40Z
dc.date.issued2015
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjective: To evaluate the effect of tumor necrosis factor-alpha (TNF-alpha) blockade on the thickness of the peripapillary retinal nerve fiber layer (RNFL), the ganglion cell-inner plexiform layers (GCIPL), and the macula in ankylosing spondylitis (AS) patients under anti-TNF-alpha therapy. Materials and methods: Twenty-one patients with AS received etanercept, or adalimumab, or infliximab for at least 6 months. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels, and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores were measured before and 6 months after the beginning of the treatment. Peripapillary RNFL, four regional fields (superior, inferior, nasal, and temporal), GCIPL, and macular thicknesses of the patients were analyzed by optical coherence tomography before the treatment, at 3 months and 6 months after the beginning of the treatment. Results: The mean BASDAI, ESR, and CRP values were 5.2 +/- 1.5, 31.6 +/- 21.7, and 15.7 +/- 13.9, respectively, at the beginning of the treatment and 2.3 +/- 1.7, 21.3 +/- 15.1, and 10.1 +/- 10.3, respectively, 6 months after the beginning of treatment. There were significant differences among the mean BASDAI, ESR, and CRP values at the beginning of treatment and 6 months later (p < 0.001, p = 0.007, and p = 0.009, respectively). There were no significant differences among peripapillary RNFL (p = 0.24), four regional fields (p = 0.98, p = 0.23, p = 0.09, p = 0.47), GCIPL (p = 0.25), or macular (p = 0.33) thicknesses of the patients during anti-TNF-alpha treatment. In addition, the mean intraocular pressure levels throughout the follow-up did not show significant variation on repeated-measures ANOVA (p = 0.77). Conclusions: TNF-alpha blockade does not seem to influence RNFL, GCIPL, or macular thickness of patients with AS in the short term.en_US
dc.identifier.doi10.3109/15569527.2014.956178
dc.identifier.endpage226en_US
dc.identifier.issn1556-9527
dc.identifier.issn1556-9535
dc.identifier.issue3en_US
dc.identifier.pmid25363064en_US
dc.identifier.scopus2-s2.0-84954156397en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage222en_US
dc.identifier.urihttps://doi.org/10.3109/15569527.2014.956178
dc.identifier.urihttps://hdl.handle.net/20.500.12483/11001
dc.identifier.volume34en_US
dc.identifier.wosWOS:000361329600009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofCutaneous and Ocular Toxicologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMacula luteaen_US
dc.subjectretinal ganglion cellen_US
dc.subjectspondylarthropathiesen_US
dc.titleSpectral domain-optical coherence tomographic findings in patients with ankylosing spondylitis under anti-tumor necrosis factor-alpha therapyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
103.35 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu